287 related articles for article (PubMed ID: 27168493)
1. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.
Karvela M; Baquero P; Kuntz EM; Mukhopadhyay A; Mitchell R; Allan EK; Chan E; Kranc KR; Calabretta B; Salomoni P; Gottlieb E; Holyoake TL; Helgason GV
Autophagy; 2016 Jun; 12(6):936-48. PubMed ID: 27168493
[TBL] [Abstract][Full Text] [Related]
2. Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
Hirao T; Yamaguchi M; Kikuya M; Chibana H; Ito K; Aoki S
Cancer Sci; 2018 Jan; 109(1):121-131. PubMed ID: 29121435
[TBL] [Abstract][Full Text] [Related]
3. Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.
Malyukova A; Ujvari D; Yektaei-Karin E; Zovko A; Madapura HS; Keszei M; Nagy N; Lotfi K; Björn N; Wallvik J; Tamai M; Nguyen TTT; Akahane K; Inukai T; Stenke L; Salamon D
Cell Death Dis; 2021 Sep; 12(10):875. PubMed ID: 34564697
[TBL] [Abstract][Full Text] [Related]
4. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Bellodi C; Lidonnici MR; Hamilton A; Helgason GV; Soliera AR; Ronchetti M; Galavotti S; Young KW; Selmi T; Yacobi R; Van Etten RA; Donato N; Hunter A; Dinsdale D; Tirrò E; Vigneri P; Nicotera P; Dyer MJ; Holyoake T; Salomoni P; Calabretta B
J Clin Invest; 2009 May; 119(5):1109-23. PubMed ID: 19363292
[TBL] [Abstract][Full Text] [Related]
5. Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells.
Qiu S; Sheth V; Yan C; Liu J; Chacko BK; Li H; Crossman DK; Fortmann SD; Aryal S; Rennhack A; Grant MB; Welner RS; Paterson AJ; Wende AR; Darley-Usmar VM; Lu R; Locasale JW; Bhatia R
Blood; 2023 Aug; 142(6):574-588. PubMed ID: 37192295
[TBL] [Abstract][Full Text] [Related]
6. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
7. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
8. AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells.
Koyama D; Kikuchi J; Kuroda Y; Ohta M; Furukawa Y
Cancer Sci; 2021 Jan; 112(1):194-204. PubMed ID: 33070465
[TBL] [Abstract][Full Text] [Related]
9. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
10. Metabolic alterations mediated by STAT3 promotes drug persistence in CML.
Patel SB; Nemkov T; Stefanoni D; Benavides GA; Bassal MA; Crown BL; Matkins VR; Camacho V; Kuznetsova V; Hoang AT; Tenen DE; Wolock SL; Park J; Ying L; Yue Z; Chen JY; Yang H; Tenen DG; Ferrell PB; Lu R; Darley-Usmar V; D'Alessandro A; Bhatia R; Welner RS
Leukemia; 2021 Dec; 35(12):3371-3382. PubMed ID: 34120146
[TBL] [Abstract][Full Text] [Related]
11. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Woessner DW; Lim CS
Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
[TBL] [Abstract][Full Text] [Related]
12. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.
Kuntz EM; Baquero P; Michie AM; Dunn K; Tardito S; Holyoake TL; Helgason GV; Gottlieb E
Nat Med; 2017 Oct; 23(10):1234-1240. PubMed ID: 28920959
[TBL] [Abstract][Full Text] [Related]
13. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
Pellicano F; Scott MT; Helgason GV; Hopcroft LE; Allan EK; Aspinall-O'Dea M; Copland M; Pierce A; Huntly BJ; Whetton AD; Holyoake TL
Stem Cells; 2014 Sep; 32(9):2324-37. PubMed ID: 24806995
[TBL] [Abstract][Full Text] [Related]
14. Autophagy Proteins ATG5 and ATG7 Are Essential for the Maintenance of Human CD34(+) Hematopoietic Stem-Progenitor Cells.
Gomez-Puerto MC; Folkerts H; Wierenga AT; Schepers K; Schuringa JJ; Coffer PJ; Vellenga E
Stem Cells; 2016 Jun; 34(6):1651-63. PubMed ID: 26930546
[TBL] [Abstract][Full Text] [Related]
15. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
[TBL] [Abstract][Full Text] [Related]
16. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
[TBL] [Abstract][Full Text] [Related]
17. Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia.
Khalaf A; de Beauchamp L; Kalkman E; Rattigan K; Himonas E; Jones J; James D; Shokry ESA; Scott MT; Dunn K; Tardito S; Copland M; Sumpton D; Shanks E; Helgason GV
Sci Transl Med; 2024 Jun; 16(751):eadi5336. PubMed ID: 38865484
[TBL] [Abstract][Full Text] [Related]
18. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
19. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Copland M; Pellicano F; Richmond L; Allan EK; Hamilton A; Lee FY; Weinmann R; Holyoake TL
Blood; 2008 Mar; 111(5):2843-53. PubMed ID: 18156496
[TBL] [Abstract][Full Text] [Related]
20. Involvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells.
Rakshit S; Mandal L; Pal BC; Bagchi J; Biswas N; Chaudhuri J; Chowdhury AA; Manna A; Chaudhuri U; Konar A; Mukherjee T; Jaisankar P; Bandyopadhyay S
Biochem Pharmacol; 2010 Dec; 80(11):1662-75. PubMed ID: 20832390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
